You are here

Drug Forecast

The First FDA-Approved Treatment for Tardive Dyskinesia
A New-Generation Lipoglycopeptide for the Treatment Of Acute Bacterial Skin and Skin Structure Infections
A Direct-Acting Oral Anticoagulant Factor Xa Inhibitor
A Novel Neuroprotective Agent for the Treatment of Amyotrophic Lateral Sclerosis
The First Monoclonal Antibody Approved to Prevent the Recurrence of a Bacterial Infection
A Once-Daily Incretin Mimetic Injection for Type-2 Diabetes
A Monoamine Oxidase B Inhibitor for the Adjunct Treatment of Motor Symptoms in Parkinson’s Disease
An Interleukin-5 Antagonist for Severe Asthma of the Eosinophilic Phenotype